Obinutuzumab
(GA101, Anti-Human CD20 type II, Humanized Antibody)
Catalog No.: PC-26993Not For Human Use, Lab Use Only.
Obinutuzumab (GA101, GA-101) is a third-generation, humanized and glyco-engineered anti-CD20 mAb, binds with high affinity to the CD20 type II epitope, resulting in the induction of antibody-dependent cytotoxicity.
Obinutuzumab (GA101, GA-101) is a third-generation, humanized and glyco-engineered anti-CD20 mAb, binds with high affinity to the CD20 type II epitope, resulting in the induction of antibody-dependent cytotoxicity. Obinutuzumab also exhibits superior direct cell killing properties than rituximab. Obinutuzumab induced dose-dependent antitumor activity, complete tumor regression and improved long-term survival in xenograft mouse models of B-cell malignancy. Isotype: Human IgG1 kappa
Physicochemical Properties
M.Wt
146.32 kDa
Formula
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
Human IgG1 kappa
References
1. Mössner E, et al. Blood. 2010 Jun 3;115(22):4393-402.
